Azacitidine Injection 100mg Citaza
Trade Name: Citaza
Manufacturer: Celon Laboratories Ltd
Presentation: Injection
Strength: 100mg
What is the purpose of the medicine Azacitidine Injection?
Azacitidine Injection is also known by its brand name Vidaza, is a cancer medication. It is a treatment for those who are unable to get high-dose stem cell transplant treatment for the following conditions: Chronic myelomonocytic leukaemia is a type of leukaemia that affects the blood cells (CMML) Acute myeloid leukaemia (AML) is a kind of leukaemia that affects (AML)
What is the best way to administer Citaza?
Azacitidine is administered by a doctor or nurse at a medical office or hospital outpatient department as a powder that is mixed with water and injected subcutaneously (under the skin) or intravenously (into a vein). It’s normally given once a day for seven days.
How quickly does azacitidine start working?
VIDAZA is a long-term therapy. Treatment cycles are administered every 28 days for as long as your doctor prescribes. Your doctor may not notice a difference for several cycles (approximately 4 to 6 months). Your symptoms may reappear if you stop taking treatment.
What are the azacitidine chemotherapy side effects?
- Fatigue.
- Hair loss is a very prevalent problem.
- Bruising and bleeding are extremely prevalent.
- Infection.
- Anaemia is a condition in which a person’s blood levels are low (low red blood cell counts)
- The most frequent negative effects are nausea and vomiting. Appetites shift with the passage of time.
- Constipation. For more details Click Here.
Can you live with azacitidine for a long time?
Patients should be treated with azacitidine for at least 6 months, and treatment should be continued in patients who achieve a documented response or stable disease (sd) until disease progression or unacceptable toxicity occurs.
Is there a distinction between azacitidine and decitabine?
Decitabine medication is substantially related with a greater ORR (P = 0.026) and longer PFS (P = 0.037) when compared to azacitidine treatment, according to multivariate analyses. In response to the two HMAs, there were no significant differences in the occurrence of grade 3 or higher hematologic adverse events.
If you are looking for another product or brand click here.